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Abstract
Background
Primaquine (PQ) is the only currently licensed antimalarial that prevents Plasmodium vivax
(Pv) relapses. It also clears mature P. falciparum (Pf) gametocytes, thereby reducing post-
treatment transmission. Randomized PQ treatment in a treatment-to-reinfection cohort in
Papua New Guinean children permitted the study of Pv and Pf gametocyte carriage after
radical cure and to investigate the contribution of Pv relapses.
Methods
Children received radical cure with Chloroquine, Artemether-Lumefantrine plus either PQ or
placebo. Blood samples were subsequently collected in 2-to 4-weekly intervals over 8
months. Gametocytes were detected by quantitative reverse transcription-PCR targeting
pvs25 and pfs25.
Results
PQ treatment reduced the incidence of Pv gametocytes by 73%, which was comparable to
the effect of PQ on incidence of blood-stage infections. 92% of Pv and 79% of Pf gameto-
cyte-positive infections were asymptomatic. Pv and to a lesser extent Pf gametocyte positiv-
ity and density were associated with high blood-stage parasite densities. Multivariate
analysis revealed that the odds of gametocytes were significantly reduced in mixed-species
infections compared to single-species infections for both species (ORPv = 0.39 [95% CI
0.25–0.62], ORPf = 0.33 [95% CI 0.18–0.60], p<0.001). No difference between the PQ and
placebo treatment arms was observed in density of Pv gametocytes or in the proportion of Pv
infections that carried gametocytes. First infections after blood-stage and placebo treatment,
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Conclusion
Pv relapses and new infections are associated with similar levels of gametocytaemia.
Relapses thus contribute considerably to the Pv reservoir highlighting the importance of
effective anti-hypnozoite treatment for efficient control of Pv.
Trial registration
ClinicalTrials.gov NCT02143934
Author summary
Plasmodium vivax (Pv) mainly affects Asia, Central and South America as well as Ethiopia.
In Papua New Guinea (PNG) Pv prevalence is among the highest worldwide. The biggest
challenge for the control of Pv infections is the formation of dormant liver stages, which
have the ability to relapse and cause disease even after successful clearance of asexual stages
in the blood circulation. Primaquine is the only licensed drug that is able to prevent Pv
relapses. A randomized treatment-to-reinfection cohort in Papua New Guinean children
permitted permitted the study of Pv and P. falciparum gametocyte carriage after radical
cure with Primaquine and to investigate the contribution of Pv relapses to transmission.
We found that most gametocyte carriers in this study were detected in asymptomatic infec-
tions and that relapses and new infections are associated with similar Pv gametocyte pro-
duction. These are strong arguments emphasizing the importance of sensitive detection
and early treatment of asymptomatic and submicroscopic Plasmodium spp. infections and
of anti-hypnozoite treatment for an effective control of Pv.
Introduction
Primaquine (PQ) is the only currently licensed drug for preventing Plasmodium vivax (Pv)
relapses [1], and also the only effective drug against mature gametocytes of P. falciparum (Pf)
[2,3]. Since 2012, the World Health Organization recommends a single dose of PQ for treat-
ment of Pf infections with the aim to reduce post-treatment Pf gametocyte carriage and thus
the potential for onward malaria transmission [4].
Gametocyte development as well as morphology differs considerably between Pv and Pf [5].
Pv gametocytes mature rapidly and are detectable in the peripheral blood as early as two or
three days following detection of blood-stage parasites by qPCR or light microscopy (LM),
respectively [6,7]. In contrast, Pf gametocytes sequester for 7–10 days in the bone marrow
before being released into the blood circulation [8], where they are observed by LM 10–15
days after the first detection of asexual parasites [9]. Gametocytes were observed in symptom-
atic Pv episodes at higher frequency compared to Pf episodes, despite 10-fold lower Pv blood-
stage densities compared to Pf [10]. After drug treatment, Pv gametocytes are cleared within
days after clearance of blood-stage infections in contrast to Pf gametocytes, which circulate
over 3 weeks following successful blood-stage clearance [6,9,11,12]. Altogether the published
data suggests that Pv infections produce proportionally higher gametocyte densities than Pf
Liver-stage clearance and Plasmodium spp. gametocytes
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infections (at the same levels of asexual parasitaemia), and that Pv gametocytes mature more
rapidly [9,12–14].
Not much is known about gametocyte production in primary Pv infections versus relapses
from activated hypnozoites, mainly because in endemic settings it is impossible to distinguish
both sources of infection. Our previous work in Papua New Guinea (PNG) showed that relaps-
ing Pv infections contributed 73% of the gametocyte carriage [15]. A study in Thailand and
Indonesia reported that densities by LM of Pv blood-stage parasites and gametocytes were sim-
ilar in new infections and relapses [16]. Both studies indicated the need for efficient treatment
of the hypnozoite reservoir for reducing Pv transmission [15,16].
A challenge in studying the investment of Pv infections in gametocytogenesis is the gener-
ally low and often submicroscopic density of asexual parasites and gametocytes. In addition,
scarce Pv gametocytes can easily be misclassified by LM due to their resemblance to late tro-
phozoites [17]. Investigating gametocyte production of Pv infections hence requires sensitive
and specific molecular methods. For Pf, studying gametocytes by LM is more feasible because
of the distinct crescent-shaped morphology of gametocytes and generally higher parasite den-
sities; however also for Pf, molecular methods are crucial for studying gametocytes in low-den-
sity Pf infections. Molecular detection of gametocytes usually targets transcripts of the Pf or Pv
25 kDa ookinete surface antigen precursor (pfs25 or pvs25, respectively) [18,19], which are
highly expressed in mature gametocytes [20,21]. Expression of the pfs25 transcripts is mainly
female specific, hence male gametocytes are detected to a much lower extend by pfs25-based
assays [22]. Female gametocytes are generally over-represented in peripheral blood samples
with about 3.5 female per each male gametocyte [23,24]. It can therefore be estimated that
pfs25 RT-qPCR assays detect approx. 70% of the total number of gametocytes. Both pfs25 and
pvs25 quantitative reverse transcription PCR (qRT-PCR) or nucleic acid sequence-based
amplification (NASBA) can detect as few as 1 Pf gametocyte or 10 Pv gametocytes per 50 μl
blood and are therefore up to 50x more sensitive than LM [18,19,25].
This study investigated gametocyte dynamics of Pf and Pv infections in school-aged PNG
children after randomized treatment with blood-stage antimalarials plus PQ or placebo. This
trial design permitted an evaluation of the contribution of hypnozoites to Pv infection parame-
ters by comparison of two treatment arms. PQ treatment for clearance of hypnozoites reduced
the risk of recurrent Pv blood-stage infection by 82% [95% CI 0.75–0.86], the risk of a Pv epi-
sode by 75% [95% CI 0.49–0.89], and the incidence of Pv gametocytes by 73% [95% CI 0.62,
0.81][15]. Another study conducted in Thailand and Indonesia revealed that density of gameto-
cytes over time followed that of asexual parasites [16]. However, the Thai-Indonesian study
depended on the presentation of patients at a health facility upon occurrence of a clinical epi-
sode and did not use molecular methods to detect submicroscopic asexual parasites or gameto-
cytes [16]. Our initial report on the PNG cohort study is now extended to address the following
questions: (i) what are risk factors for Pf and Pv gametocyte carriage? (ii) does gametocytaemia
differ between Pv new infections and relapses? And (iii) does PQ treatment exert a long-term
effect on Pf and Pv gametocytaemia?
Methods
Study design
The study was conducted in 2009 to 2010 in the Albinama area, East Sepik province, in PNG.
A detailed study protocol has been published previously [15]. In brief, 504 children aged 5 to
10 years were randomized to two treatment arms and completed directly observed treatment
(DOT) with a 3-day dose of Chloroquine (CQ), a 3-day dose of Artemether-Lumefantrine
(AL) and either 20 doses of PQ (per day: 0.5 mg/kg) or placebo over four weeks. Children were
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screened for G6PD deficiency by using a visual colorimetric method (G6PD Assay Kit
WST-Dojindo Co., Japan). Venous blood samples were collected at enrolment (prior to treat-
ment) and 3 days after the final dose of DOT. The latter date represented day 0 of follow-up.
Finger-prick samples were taken every two weeks for the first 3 months and monthly for the
remaining 5 months of follow-up. Symptomatic children detected during follow-up were
treated with a 3-day course of AL after confirming Plasmodium infection by rapid diagnostic
test (RDT, CareStart Malaria pLDH/HRP2 Combo, AccessBio, USA).
Ethics statement. The study received ethical clearance by the PNG Institute of Medical
Research (IMR) Institutional Review Board (0908), the PNG Medical Advisory Committee
(09.11), the Ethikkommission beider Basel (237/11) and was registered on ClinicalTrials.gov
NCT02143934. A parent or guardian of every child participant provided written informed
consent for their participation.
Detection of blood-stage parasites and gametocytes
All blood samples collected were examined by LM and quantitative PCR (qPCR). Blood slides
were examined by at least two independent microscopists and declared parasite negative only
after examination of 200 thick-film fields [15]. Parasite DNA was extracted from 100–150 μl
blood cell pellet using the FavorPrep 96-well genomic DNA extraction kit (Favorgen, Taiwan)
and analyzed for Pf and Pv positivity by 18S rRNA qPCR [15,19]. All Pv and Pf qPCR positive
samples were genotyped using markers Pv-msp1F3 and Pf-msp2, respectively, following previ-
ously published protocols [26,27].
RNA was extracted from all samples positive in Pf or Pv qPCR. RNA was extracted using
the RNEasy 96 kit (Qiagen, Switzerland) as described previously [19] from 50μl whole blood
spotted on filter papers that had been air-dried and stored in TRIzol reagent (Life Technolo-
gies, Switzerland). Gametocyte-specific transcripts were detected by pfs25 or pvs25 qRT-PCR
[19] in all RNA samples for which the corresponding DNA sample had been positive by spe-
cies-specific qPCR.
Statistical analysis
Children were censored on the last visit before two consecutively missed scheduled follow-up
visits [15]. Comparison of LM-positive versus submicroscopic infections, and symptomatic
versus asymptomatic infections was performed with 5019 samples from the follow-up period
for which LM data was available. A clinical malaria episode was defined as fever (axillary tem-
perature >37.5˚C and/or fever reported in previous 2 days) and the presence of Plasmodium
spp. parasites by LM. Differences in proportions were tested for statistical significance using
the McNemar X2 test with continuity correction. To achieve normal distribution, qPCR densi-
ties were expressed as log10-transformed 18S rRNA genomic copies/μl blood for asexual para-
sites, and log10-transformed pfs25 or pvs25 transcripts/μl blood for gametocytes. Correlation
between microscopic parasite counts and molecular methods was tested by Kendall’s rank sum
test on log10 transformed data. Geometric means of densities were calculated. Differences in
densities of asexual or sexual-stage parasites were tested for statistical significance using
Welch’s Two-sample t-test.
Negative binomial regression models were used to calculate the incidence rate of Pv and Pf
gametocyte positivity as previously described [15]. Gametocyte positivity during follow-up
was modeled using binomial generalized estimating equations (GEE) with logit link using an
exchangeable correlation matrix to account for repeated measures by child. Log10-transformed
blood-stage parasite density and gametocyte density during follow-up were modeled using
Gaussian GEEs with log link using an exchangeable correlation matrix. Linear fit for log10-
Liver-stage clearance and Plasmodium spp. gametocytes
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transformed blood-stage parasite density was previously analyzed and considered adequate for
both species (S1 Text). All Models were back-selected. Statistical analyses were conducted
using R version 3.1.1 [28] or STATA version 14.
Results
Gametocyte positivity and density in submicroscopic infections
Molecular methods were superior to LM especially for detection of gametocytes but also for
blood-stage parasites (Fig 1). By LM Pv gametocytes were detected in only 44 out of 366 Pv
positive samples (12%), whereas by molecular detection 265 out of 705 Pv samples (38%,
p<0.001) were gametocyte-positive. Pf gametocyte rates by LM were 21% (52/237) and by
qRT-PCR 25% (107/426). 84% [CI95: 79–88%] and 53% [CI95: 43–63%] gametocytaemia was
submicroscopic, for Pv and Pf respectively (Fig 1A and 1D). In one Pv and two Pf samples
gametocytes were detected by LM but not by qRT-PCR, indicating most probably RNA degra-
dation. For Pv infections, a late-stage trophozoite can be misread as a gametocyte, however
LM slides of this study were read by three independent microscopists. Overall, gametocyte
densities by LM and by molecular methods were significantly correlated in samples positive by
both methods (Kendall’s tau test, pvs25: tau = 0.24, p-value = 0.037, pfs25: tau = 0.23, p-value =
0.027). Due to the low sensitivity of LM in gametocyte detection, all further results presented
here derive from molecular gametocyte detection.
Significantly more Pv infections carried qRT-PCR detectable gametocytes compared to Pf
(38% vs. 25%, p<0.001). Microscopically patent infections of both species carried gametocytes
more often than submicroscopic infections (Pv: 48% vs. 27%, Pf: 35% vs. 13%, p<0.001, Fig 1B
and 1E). Similarly, gametocyte-specific transcript numbers were significantly higher in LM-
positive than LM-negative samples for both species (S1 Fig).
Gametocyte positivity and density in symptomatic versus asymptomatic
infections
During the follow-up period, 34 Pv episodes and 68 Pf clinical episodes were observed. The
proportion of gametocyte carriers was 22% higher in clinical episodes compared to asymptom-
atic P. vivax infections (59% vs. 37%, p = 0.014, Fig 1C). For P. falciparum, a similar trend was
observed but did not reach statistical significance (34% vs. 23%, p = 0.098, Fig 1F). However,
due to a much higher number of asymptomatic infections than clinical episodes, the over-
whelming majority of Pv and Pf gametocyte carriage (92% [CI95: 88–95%] and 79% [CI95: 69–
86%]) occurred in asymptomatic children. Pv gametocyte densities showed the same trend as
asexual densities in both clinical episodes and asymptomatic infections, but this was not the
case for Pf (S2 Fig).
The effect of PQ treatment on gametocytaemia during follow-up
Pv gametocyte prevalence increased steadily throughout the follow-up period and was on aver-
age almost 3-fold higher in the placebo arm than in the PQ arm, similar to patterns observed
in Pv blood-stage parasite prevalence (Pv gametocytes median fold difference PL>PQ: 2.9
[IQR: 2.0–3.8], Pv blood-stages median fold difference PL>PQ: 2.8 [IQR: 2.2–4.2], Fig 2A).
No difference in Pf gametocyte prevalence was observed between study arms (Pf gametocytes
median fold difference PL>PQ 1.0 [IQR: 0.7–1.4], Pf blood-stages median fold difference
PL>PQ: 1.1 [IQR: 0.9–1.3], Fig 2B).
To assess in detail Pv gametocyte production in primary infections versus relapses, we com-
pared gametocyte positivity and density in first infections after blood-stage plus placebo (first
Liver-stage clearance and Plasmodium spp. gametocytes
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Pv infection either from relapse (80%80%) or infective bite (20%)) or blood-stage plus PQ
treatment (first Pv infection always from infective bite) [15]. We also assessed subsequent Pv
infections, i.e. all but the first parasite-positive sample per child, which in both arms can result
from an ongoing infection, a relapsing hypnozoite or a new infection from a mosquito. First
Pv re-infections after baseline treatment were equally likely to carry gametocytes in both
Fig 1. Pv (top) and Pf (bottom) gametocyte positivity among 5019 follow-up samples. (A, D) Detection of blood stage parasites and gametocytes by
LM and molecular methods, using pv18S or pf18S rRNA qPCR for detection of blood-stage parasites and pvs25 or pfs25 qRT-PCR for detection of
gametocytes. Black: gametocyte positive samples. White: parasite positive samples without gametocytes. (B, E) Proportion of gametocytes positives (by
molecular methods) in submicroscopic and LM-positive samples. (C, F) Proportion of gametocyte positives (by molecular methods) in symptomatic and
asymptomatic infections. Error bars indicate 95% confidence intervals by X2 distribution.
https://doi.org/10.1371/journal.pntd.0005753.g001
Liver-stage clearance and Plasmodium spp. gametocytes
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treatment arms (PQ: 29% vs. Placebo: 31%, Fig 3A), and the same was observed for subsequent
infections (PQ: 42% [CI95: 32–52%] vs. Placebo: 41% [CI95: 36–47%], p = 1). To investigate
whether gametocyte densities were simply following the asexual densities or if other factors
play a role, we compared absolute as well as normalized gametocyte densities. Gametocyte
densities were normalized by dividing pvs25 or pfs25 transcript numbers/μl by Pv- or Pf-18S
rRNA copy numbers/μl. Absolute and normalized Pv gametocyte densities did not differ
between treatment arms in first infections (Fig 3B and 3C) nor in subsequent infections (S3
Fig).
We also investigated Pf gametocyte carriage by comparing Pf gametocyte positivity and
density in first Pf infections after treatment. Significantly more Pf gametocyte carriers were
observed among first infections in the PQ-arm compared to the placebo arm (PQ: 26% vs. Pla-
cebo: 10%, Fig 3D). No significant difference between trial arms was observed in subsequent
samples (PQ: 30% [CI95 22–39%] vs. Placebo: 31% [CI95 23–40%], p = 0.961). Pf absolute and
normalized gametocyte densities did not differ significantly between the treatment arms (Fig
3E and 3F, S3 Fig).
Risk factors for gametocytes positivity and density
Pv gametocytes were detected more frequently (Table 1, OR for 1-log increase of density = 1.95,
p<0.001) and in higher densities (Table 2, p<0.001) with increasing blood-stage parasite den-
sity. Apart from reducing the number of Pv positive samples during follow-up (S1 Table), PQ
treatment had no further effect on Pv gametocyte positivity (Table 1).
In Pv positive samples, the odds of Pv gametocytes were 60% reduced and gametocyte den-
sities were 30% lower in mixed Pf/Pv infections compared to single-species Pv infections
(Table 1, p<0.001; Table 2 p = 0.003). The odds for Pv gametocyte carriage increased signifi-
cantly over the whole follow-up period (Table 1 and Fig 2, p<0.001), and a 36% reduction on
the odds of being gametocyte positive was observed in first Pv infections compared to subse-
quent infections (Table 1, p = 0.040). No other factors were associated with the odds for Pv
gametocyte carriage during follow-up (Table 1). Pv gametocyte density, but not positivity,
decreased with age (Table 2, p = 0.017) following the age trend in asexual parasites (Table 3,
[29]).
Fig 2. Prevalence of blood-stage parasites and gametocytes of Pv (A) and Pf (B) during follow-up by treatment arm.
https://doi.org/10.1371/journal.pntd.0005753.g002
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As for Pv gametocytes, the odds for Pf gametocytes were 70% reduced in mixed Pf/Pv infec-
tions compared to single-species Pf infections (Table 1, p<0.001). As an effect of delayed Pf
gametocyte maturation, gametocyte positivity was 55% lower in first Pf infections compared to
subsequent infections (Table 1, p = 0.007). Other risk factors for Pf gametocytes were investi-
gated, but none of the parameters tested was significant. The Pf gametocyte positivity was
Fig 3. Gametocyte positivity and density in first Pv (top) and Pf (bottom) infections after treatment with blood-stage antimalarials alone
(placebo) or blood-stage antimalarials plus PQ (PQ). (A, D). Proportion of Pv and Pf gametocyte carriers among first infections by treatment arm.
Figures within the bars indicate absolute numbers of gametocyte-positive first infections following treatment. Error bars indicate 95% confidence intervals by
X2 distribution. (B, E). Normalized Pv and Pf gametocyte densities in first infections by treatment arm. Densities were normalized by dividing pvs25 or pfs25
transcript numbers/μl by Pv- or Pf-18S rRNA copy numbers/μl. (C, F) Absolute Pv and Pf gametocyte densities in first infections by treatment arm. Densities
are expressed as log10 of pvs25 and pfs25 transcripts/μl.
https://doi.org/10.1371/journal.pntd.0005753.g003
Liver-stage clearance and Plasmodium spp. gametocytes
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slightly higher in samples with high asexual densities, yet this association did not reach the 5%
significance level (Table 1, OR for 1-log increase of density = 1.23, p = 0.059). In contrast to Pv,
Pf gametocyte densities were not associated with any of the factors assessed (S1 Text). Fever
was strongly associated with increasing blood-stage Pf parasitaemia (Table 3, OR = 2.41,
p<0.001), but had no effect on gametocyte density.
Analysis of only subsequent infections showed similar results to the analysis of the entire fol-
low-up period (S2 Table). Considering subsequent infections only, Pv gametocytes were
reduced by 47% [13–68%] and Pf gametocytes were reduced by 63% [26–82%] in mixed-species
infections compared to single-species infections (Pv p-value: 0.013, Pf p-value: 0.006, S2 Table).
It was not possible to analyse the effect of mixed-species co-infection on gametocyte carriage in
first positive samples following treatment due to very low sample size for either species.
Table 1. Multivariable predictors of Pv and Pf gametocyte positivity during follow-up.
Pv gametocyte positive Pf gametocyte positive
OR 95% CI p-value OR 95% CI p-value
Blood-stage density (by qPCR), per 10x increase 1.95 1.47 2.58 <0.001 1.23 0.99 1.51 0.059
PQ treatment 1.03 0.68 1.58 0.878 1.21 0.78 1.90 0.395
Mixed Pf/Pv (by qPCR) 0.39 0.25 0.62 <0.001 0.33 0.18 0.60 <0.001
First infection 0.64 0.42 0.98 0.040 0.45 0.25 0.81 0.007
Days after DOT (ref:0–60)
61–120 0.59 0.39 0.89 1.31 0.62 2.76
121–180 1.48 0.91 2.42 <0.001 1.32 0.63 2.75 0.266
>180 2.54 1.47 4.39 0.73 0.32 1.67
Constant 0.36 0.22 0.59 <0.001 0.29 0.11 0.77 <0.013
OR, odds ratio
DOT, directly observed treatment.
ORs were obtained using binomial generalized estimating equations with logit-link allowing for repeated visits by back-selection from the full model. The full
model included fever, infection status at enrolment by qPCR (Pf or Pv positive), LLIN use (less than 100%), sex, village of residence, hemoglobin at
baseline (>9 g/dl), age. No significant interaction of PQ treatment with days post DOT was detected.
https://doi.org/10.1371/journal.pntd.0005753.t001
Table 2. Multivariable predictors of Pv and Pf gametocyte density during follow-up.
Pv gametocyte density
exp(β) 95% CI p-value
Blood-stage density (by qPCR) per 10x increase 1.37 1.20 1.56 <0.001
PQ treatment 0.97 0.80 1.18 0.765
Mixed Pf/Pv (by qPCR) 0.73 0.59 0.90 0.003
Age 0.94 0.89 0.99 0.017
Days after DOT (ref: 0–60)
61–120 1.08 0.86 1.35
121–180 1.15 0.90 1.47 0.163
>180 1.30 1.03 1.64
Constant 1.11 0.69 1.81 0.661
β, regression coefficient.
Coefficients were obtained using Gaussian generalized estimating equations with log-link by allowing for
repeated visits and by back-selection from the full model. The full model included fever, infection status at
enrolment by qPCR (Pf or Pv positive), LLIN use (less than 100%), sex, village of residence, hemoglobin at
baseline (>9 g/dl), first infection. No predictors were associated with Pf gametocyte densities (S1 Text). No
significant interaction of PQ treatment with days post DOT was detected.
https://doi.org/10.1371/journal.pntd.0005753.t002
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Discussion
This study represents a first detailed investigation of the contribution of Pv relapses to the
infectious reservoir. The transmission potential attributable to relapses was estimated by com-
paring gametocyte positivity and density in children that had received either PQ or placebo
treatment. A major finding was that Pv gametocytes were detected in equal proportions and
equal density in Pv positive samples of both trial arms. In the PQ arm, the majority of Pv infec-
tions derived from new mosquito bites, while in the placebo arm 80% of infections were caused
by relapsing hypnozoites [15]. Gametocyte densities as well as the proportion of gametocyte
carriers concurred in both arms, thus indicating that new and relapsing infections produce
gametocytes at equal rates. Similar conclusions were drawn from a study in south-east Asia,
where Pv gametocyte densities and positivity had closely mirrored parasitaemia in both, clini-
cal primary and recurrent infections [16]. Gametocyte production in relapses thus seems indis-
tinguishable from that in new infections. This finding highlights the importance of anti-
hypnozoite drugs to prevent relapses for an effective interruption of Pv transmission.
Sample storage in this cohort was not optimal for RNA preservation. Blood was spotted
onto Whatman 3MM filter paper in the field, and stored at room temperature for up to 5
weeks until transferred into TRIzol reagent. This procedure was suboptimal compared to sam-
pling in RNA-stabilizing reagents [19]. A more recent cross-sectional study in PNG employed
sampling in RNAprotect Cell Reagent (Qiagen, Switzerland) and found gametocytes in 78%
and 60% of Pf and Pv qPCR-positive samples in children aged 6–9 years [25]. Almost universal
Pv gametocyte prevalence (95%) was found in Brazilian samples stored in liquid nitrogen [30].
The relatively low gametocyte positivity in this cohort was indicative of poor RNA quality,
which likely resulted in a substantial underestimation of gametocyte rates. The gametocyte
rate in the present study thus reflects a minimum prevalence. Because RNA quality and sample
volume did not vary within the study, the comparative analyses of treatment arms and risk fac-
tors remain unaffected, even if these results need to be regarded as referring to infections with
moderately high gametocyte densities.
The vast majority (>80%) of gametocyte carriers were asymptomatic for both species, and
over 20% of Pv and over 30% of Pf gametocyte positive samples were submicroscopic.
Table 3. Multivariate predictors Pv and Pf blood-stage parasite density during follow-up.
Pv blood-stage density Pf blood-stage density
exp(β) 95% CI p-value exp(β) 95% CI p-value
PQ treatment 1.04 0.93 1.15 0.505 0.85 0.68 1.06 0.143
Mixed Pf/Pv (by qPCR) - - - - 0.79 0.63 1.00 0.048
Fever - - - - 2.41 1.82 3.19 <0.001
Age 0.96 0.92 0.99 0.014 - - - -
Days after DOT (ref: 0–60)
61–120 0.94 0.83 1.07 0.93 0.69 1.25
121–180 0.72 0.62 0.83 <0.001 0.89 0.62 1.25 <0.001
>180 0.51 0.44 0.59 0.59 0.43 0.80
Constant 5.13 3.83 6.87 <0.001 16.37 12.37 21.66 <0.001
β, regression coefficient.
Coefficients were obtained using Gaussian generalized estimating equations with log-link by allowing for repeated visits and by back-selection from the full
model. The full model included fever, infection status at enrolment by qPCR (f. or v. positive), LLIN use (less than 100%), sex, village of residence,
hemoglobin at baseline (>9 g/dl), first infection. Non-associated predictors were shown by “-”in the respective line. No significant interaction of PQ treatment
with days post DOT was detected.
https://doi.org/10.1371/journal.pntd.0005753.t003
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Although gametocyte densities were lower in submicroscopic infections compared to LM-pos-
itive infections for both species, they may nonetheless be potentially infective to mosquitoes.
Mosquito feeding experiments have demonstrated that submicroscopic infections can infect
mosquitoes, albeit at lower rates than microscopically patent infections, and thus contribute to
onward transmission [31–35]. Our results highlight the importance of treating all malaria
infections in the community, as asymptomatic individuals will not report themselves to health
facilities and thus generally remain untreated and infectious for longer periods.
Co-infections with both species are common in PNG [36,37] including in this cohort,
and interactions between co-infecting species in mixed infections have been investigated
previously. However, these former studies focused on the asexual stages of Pv and Pf [38,39]
or risk for clinical diseases [29,38,40] and did not address transmission stages. Gametocytes
in the host are influenced by a complex interplay of parasite factors (such as stress response)
and host factors (such as immunity), and this complexity is enhanced by a second co-infect-
ing Plasmodium species. Our finding of significantly reduced gametocytes in mixed-species
infections compared to single-species infections is a first indication of species interaction
affecting the transmission stages. Confirmation of our results is required in other studies
investigating Plasmodium species interactions with specific focus on the transmission
stages.
In the first post-treatment Pf infections gametocytes were more frequently detected in the
PQ arm than in the placebo arm. This is likely explained by the slower acquisition of new Pv
infections in PQ-treated individuals, compared to a fast relapse rate in individuals retaining
hypnozoites in the liver. Indeed, in the placebo arm 52% of first Pf infections carried a Pv co-
infection as opposed to only 21% in the PQ arm. Accordingly, the multivariate analysis showed
reduced odds of Pf as well as Pv gametocytes in mixed-species infections compared to single-
species infections. In addition, a Pf co-infection reduced Pv gametocyte densities by half. A
study in 0.5 to 5 year old PNG children with uncomplicated malaria confirmed that Pv game-
tocytaemia in Pf/Pv mixed infections was reduced compared to Pv single infections [41].
Moreover, a community study in PNG showed a lower proportion of Pf gametocyte carriers in
Pf/Pv mixed infections compared to Pf single-species infections [25]. Similar findings had
been reported from Thailand [42]. More longitudinal studies designed specifically to address
gametocyte dynamics in mono- and mixed-species infections are needed to confirm potential
cross-species interaction and its effect on sexual stage development.
Conclusion
Onset and rate of Pv gametocyte production did not differ between relapses and primary infec-
tions. This is a strong argument for treatment policies and elimination strategies that support
PQ treatment of all Pv infections. The vast majority of gametocyte carriers in this study were
detected in asymptomatic infections, which suggests that sensitive detection and early treat-
ment of asymptomatic and submicroscopic Plasmodium spp. infections may be crucial for an
effective control of transmission. PQ treatment prevented relapses and thus reduced Pv game-
tocyte carriage by 73%. These and other Plasmodium species interactions that can substantially
affect gametocyte production warrant further investigation.
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